Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 32.38 Billion KRW | 28.59% |
| 2022 | 25.18 Billion KRW | 23.4% |
| 2021 | 20.4 Billion KRW | 2.6% |
| 2020 | 19.89 Billion KRW | 45.01% |
| 2019 | 13.71 Billion KRW | -11.61% |
| 2018 | 15.51 Billion KRW | -5.67% |
| 2017 | 16.45 Billion KRW | -6.66% |
| 2016 | 17.62 Billion KRW | -11.51% |
| 2015 | 19.91 Billion KRW | 4.7% |
| 2014 | 19.02 Billion KRW | 5.09% |
| 2013 | 18.1 Billion KRW | 5.72% |
| 2012 | 17.12 Billion KRW | 17.28% |
| 2011 | 14.6 Billion KRW | -25.88% |
| 2010 | 19.69 Billion KRW | -1.61% |
| 2009 | 20.02 Billion KRW | 19.94% |
| 2008 | 16.69 Billion KRW | 19.7% |
| 2007 | 13.94 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 30.78 Billion KRW | -2.34% |
| 2024 Q1 | 31.52 Billion KRW | -2.65% |
| 2023 Q3 | 26.74 Billion KRW | 6.25% |
| 2023 Q4 | 32.38 Billion KRW | 21.1% |
| 2023 FY | 32.38 Billion KRW | 28.59% |
| 2023 Q1 | 26.45 Billion KRW | 5.06% |
| 2023 Q2 | 25.16 Billion KRW | -4.87% |
| 2022 FY | 25.18 Billion KRW | 23.4% |
| 2022 Q2 | 20.88 Billion KRW | 9.05% |
| 2022 Q1 | 19.14 Billion KRW | -6.17% |
| 2022 Q4 | 25.18 Billion KRW | 16.31% |
| 2022 Q3 | 21.65 Billion KRW | 3.68% |
| 2021 Q2 | 22.77 Billion KRW | 7.57% |
| 2021 FY | 20.4 Billion KRW | 2.6% |
| 2021 Q1 | 21.16 Billion KRW | 6.42% |
| 2021 Q3 | 22.3 Billion KRW | -2.05% |
| 2021 Q4 | 20.4 Billion KRW | -8.5% |
| 2020 FY | 19.89 Billion KRW | 45.01% |
| 2020 Q4 | 19.89 Billion KRW | 1.46% |
| 2020 Q1 | 17.36 Billion KRW | 26.59% |
| 2020 Q3 | 19.6 Billion KRW | 14.2% |
| 2020 Q2 | 17.16 Billion KRW | -1.14% |
| 2019 Q4 | 13.71 Billion KRW | -5.22% |
| 2019 FY | 13.71 Billion KRW | -11.61% |
| 2019 Q1 | 14.38 Billion KRW | -7.34% |
| 2019 Q2 | 15.54 Billion KRW | 8.09% |
| 2019 Q3 | 14.47 Billion KRW | -6.89% |
| 2018 Q4 | 15.51 Billion KRW | -7.94% |
| 2018 Q1 | 17.03 Billion KRW | 3.56% |
| 2018 FY | 15.51 Billion KRW | -5.67% |
| 2018 Q2 | 17.96 Billion KRW | 5.43% |
| 2018 Q3 | 16.85 Billion KRW | -6.16% |
| 2017 Q2 | 16.3 Billion KRW | -6.33% |
| 2017 FY | 16.45 Billion KRW | -6.66% |
| 2017 Q4 | 16.45 Billion KRW | 7.01% |
| 2017 Q3 | 15.37 Billion KRW | -5.68% |
| 2017 Q1 | 17.4 Billion KRW | -1.27% |
| 2016 Q3 | 17.33 Billion KRW | 2.61% |
| 2016 FY | 17.62 Billion KRW | -11.51% |
| 2016 Q1 | 16.63 Billion KRW | -16.47% |
| 2016 Q2 | 16.89 Billion KRW | 1.55% |
| 2016 Q4 | 17.62 Billion KRW | 1.67% |
| 2015 Q1 | 16.84 Billion KRW | -11.46% |
| 2015 FY | 19.91 Billion KRW | 4.7% |
| 2015 Q4 | 19.91 Billion KRW | 1.2% |
| 2015 Q3 | 19.68 Billion KRW | 14.35% |
| 2015 Q2 | 17.21 Billion KRW | 2.18% |
| 2014 Q1 | 15.77 Billion KRW | -12.86% |
| 2014 FY | 19.02 Billion KRW | 5.09% |
| 2014 Q2 | 16.51 Billion KRW | 4.68% |
| 2014 Q4 | 19.02 Billion KRW | 16.88% |
| 2014 Q3 | 16.27 Billion KRW | -1.42% |
| 2013 Q4 | 18.1 Billion KRW | 7.44% |
| 2013 FY | 18.1 Billion KRW | 5.72% |
| 2013 Q1 | 15.22 Billion KRW | -11.08% |
| 2013 Q2 | 15.36 Billion KRW | 0.92% |
| 2013 Q3 | 16.84 Billion KRW | 9.64% |
| 2012 FY | 17.12 Billion KRW | 17.28% |
| 2012 Q4 | 17.12 Billion KRW | 0.0% |
| 2012 Q1 | 13.54 Billion KRW | 0.0% |
| 2011 FY | 14.6 Billion KRW | -25.88% |
| 2011 Q3 | 14.53 Billion KRW | -8.13% |
| 2011 Q1 | 18.43 Billion KRW | -6.41% |
| 2011 Q2 | 15.82 Billion KRW | -14.16% |
| 2010 Q3 | 23.19 Billion KRW | 2.88% |
| 2010 Q1 | 20.26 Billion KRW | 1.2% |
| 2010 Q2 | 22.54 Billion KRW | 11.26% |
| 2010 FY | 19.69 Billion KRW | -1.61% |
| 2010 Q4 | 19.69 Billion KRW | -15.07% |
| 2009 FY | 20.02 Billion KRW | 19.94% |
| 2009 Q4 | 20.02 Billion KRW | -13.13% |
| 2009 Q3 | 23.04 Billion KRW | 5.4% |
| 2009 Q2 | 21.86 Billion KRW | 14.57% |
| 2009 Q1 | 19.08 Billion KRW | 14.34% |
| 2008 Q2 | 14.63 Billion KRW | 7.6% |
| 2008 Q1 | 13.59 Billion KRW | -2.49% |
| 2008 Q3 | 14.72 Billion KRW | 0.62% |
| 2008 Q4 | 16.69 Billion KRW | 13.38% |
| 2008 FY | 16.69 Billion KRW | 19.7% |
| 2007 Q3 | 14.9 Billion KRW | 5.97% |
| 2007 Q1 | 14.03 Billion KRW | 0.0% |
| 2007 Q2 | 14.06 Billion KRW | 0.21% |
| 2007 FY | 13.94 Billion KRW | 0.0% |
| 2007 Q4 | 13.94 Billion KRW | -6.45% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.653% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 72.521% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 64.478% |
| HANDOK Inc. | 94.46 Billion KRW | 65.718% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -52.446% |
| Yuhan Corporation | 284.75 Billion KRW | 88.628% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 72.158% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -99.181% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 88.787% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 47.534% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -66.268% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -6.948% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | 33.018% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.653% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -3.66% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | 7.938% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | 32.713% |
| JW Holdings Corporation | 147.58 Billion KRW | 78.058% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 61.731% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 87.613% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.475% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 39.944% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -19.95% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | 0.391% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 70.498% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | 26.653% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 82.833% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 86.593% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.475% |
| Yuhan Corporation | 284.75 Billion KRW | 88.628% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 74.151% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 47.756% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 87.537% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 69.475% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 59.318% |
| Korea United Pharm Inc. | 49.14 Billion KRW | 34.101% |
| CKD Bio Corp. | 69.08 Billion KRW | 53.122% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 69.181% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 54.193% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 40.094% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 39.944% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 83.373% |
| Boryung Corporation | 189.8 Billion KRW | 82.938% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 43.018% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 47.534% |
| JW Lifescience Corporation | 23.39 Billion KRW | -38.402% |